Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 12/20 | 0.69 |
| ▸ | AKT1S1 | Q96B36 | 4/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.56 |
| ▸ | AKT2 | P31751 | 6/20 | 0.56 |
| ▸ | AKT3 | Q9Y243 | 6/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.56 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390419 | 0.82 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3KCNH2 | |
| SCHEMBL11027365 | 0.82 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3KCNH2 | |
| SCHEMBL10193560 | 0.77 | AKT1 (0.70) | AKT1AKT1S1ROCK2AKT2AKT3 | |
| SCHEMBL13657173 | 0.77 | AKT2 (0.68) | AKT1AKT1S1ROCK2AKT2AKT3 | |
| SCHEMBL11946592 | 0.76 | RPS6KB1 (0.70) | AKT1ROCK2AKT2AKT3KCNH2 | |
| SCHEMBL11946761 | 0.76 | RPS6KB1 (0.70) | AKT1ROCK2AKT2AKT3KCNH2 | |
| SCHEMBL10194438 | 0.75 | AKT1 (0.71) | AKT1ROCK2AKT2AKT3KCNH2 | |
| SCHEMBL11946903 | 0.74 | AKT1 (0.70) | AKT1ROCK2AKT2AKT3KCNH2 | |
| SCHEMBL13369029 | 0.74 | AKT2 (0.55) | AKT1AKT1S1ROCK2AKT2AKT3 | |
| SCHEMBL10193564 | 0.74 | AKT1 (0.71) | AKT1ROCK2AKT2AKT3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101623-B2 | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor | ASTRAZENECA AB (SE) | 2012-01-24 | — | — | US | disclosed |
| US-20090163524-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163524-A1 | Novel Protein Kinase B Inhibitors - 060 | PRKAR2B, PRKCB, MAP3K20 | AKT1 4/4885AKT1S1 84/4885ROCK2 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.